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Abstract
Ischaemia-reperfusion (IR) injury occurs when blood supply to an organ is disrupted and then 
restored, and underlies many disorders, notably heart attack and stroke. While reperfusion of 
ischaemic tissue is essential for survival, it also initiates oxidative damage, cell death, and aberrant 
immune responses through generation of mitochondrial reactive oxygen species (ROS)1-5. 
Although mitochondrial ROS production in IR is established, it has generally been considered a 
non-specific response to reperfusion1,3. Here, we developed a comparative in vivo metabolomic 
analysis and unexpectedly identified widely conserved metabolic pathways responsible for 
mitochondrial ROS production during IR. We showed that selective accumulation of the citric 
acid cycle (CAC) intermediate succinate is a universal metabolic signature of ischaemia in a range 
of tissues and is responsible for mitochondrial ROS production during reperfusion. Ischaemic 
succinate accumulation arises from reversal of succinate dehydrogenase (SDH), which in turn is 
driven by fumarate overflow from purine nucleotide breakdown and partial reversal of the malate/
aspartate shuttle. Upon reperfusion, the accumulated succinate is rapidly re-oxidised by SDH, 
driving extensive ROS generation by reverse electron transport (RET) at mitochondrial complex I. 
Decreasing ischaemic succinate accumulation by pharmacological inhibition is sufficient to 
ameliorate in vivo IR injury in murine models of heart attack and stroke. Thus, we have identified 
a conserved metabolic response of tissues to ischaemia and reperfusion that unifies many hitherto 
unconnected aspects of IR injury. Furthermore, these findings reveal a novel pathway for 
metabolic control of ROS production in vivo, while demonstrating that inhibition of ischaemic 
succinate accumulation and its oxidation upon subsequent reperfusion is a potential therapeutic 
target to decrease IR injury in a range of pathologies.
Mitochondrial ROS production is a critical early driver of IR injury, but has been considered 
a non-specific consequence of the interaction of a dysfunctional respiratory chain with 
oxygen during reperfusion1-4. Here we investigated an alternative hypothesis: that 
mitochondrial ROS during IR are generated by a specific metabolic process. To do this we 
developed a comparative metabolomics approach to identify conserved metabolic signatures 
in tissues during IR that might indicate the source of mitochondrial ROS (Fig. 1a). Liquid 
chromatography-mass spectrometry (LC-MS)-based metabolomic analysis of murine brain, 
kidney, liver and heart subjected to ischaemia in vivo (Fig. 1a) revealed changes in several 
metabolites (Supplementary Table 1). However, comparative analysis (Supplementary 
Tables 2 and 3) revealed only three were elevated across all tissues (Fig. 1b, c, and Extended 
Data Fig. 1a). Two metabolites were well-characterised by-products of ischaemic purine 
nucleotide breakdown, xanthine and hypoxanthine6, corroborating the validity of our 
approach. Xanthine and hypoxanthine are metabolised by cytosolic xanthine oxidoreductase 
and do not contribute to mitochondrial metabolism7. The third metabolite, the mitochondrial 
CAC intermediate succinate, increased 3- to 19-fold to concentrations of 61-729 ng/mg wet 
weight across the tested tissues (Fig. 1d, Supplementary Table 4 and Extended Data Fig. 
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1b,c) and was the sole mitochondrial feature of ischaemia that occurred universally in a 
range of metabolically diverse tissues. Therefore we focused on the potential role of 
succinate in mitochondrial ROS production during IR.
Since mitochondrial ROS production occurs early in reperfusion1-4,8,9, it follows that 
metabolites fuelling ROS should be oxidised quickly. Strikingly, the succinate accumulated 
during ischaemia was restored to normoxic levels by 5 minutes reperfusion ex vivo in the 
heart (Fig. 1e), and this was also observed in vivo in the heart (Fig. 1f and Extended Data 
Fig. 2a), brain (Fig. 1g) and kidney (Fig. 1h). Of note, the accumulation of succinate by the 
in vivo heart was proportional to the duration of ischaemia (Extended Data Fig. 2a). These 
changes in succinate were localised to areas of the tissues where IR injury occurred in vivo, 
and took place without accumulation of other CAC metabolites (Fig. 1f-h). These data 
demonstrate that, uniquely, succinate accumulates dramatically during ischaemia and is then 
rapidly metabolised upon reperfusion at the same time as mitochondrial ROS production 
increases.
To determine the mechanisms responsible for succinate accumulation during ischaemia and 
explore its role in IR injury we focused on the heart, because of the many experimental and 
theoretical resources available. In mammalian tissues succinate is generated by the CAC, via 
oxidation of carbons from glucose, fatty acids, glutamate, and the γ-aminobutyric acid 
(GABA) shunt (Fig. 2a, Extended Data Fig. 2b)10,11. To assess the contribution of these 
carbon sources to the build-up of ischaemic succinate we performed an array of 13C-
isotopologue labeling experiments in the ex vivo perfused heart followed by LC-MS 
analyses. Glucose is a major carbon source for the CAC therefore ischaemic CAC flux to 
succinate was first investigated by measuring its isotopologue distribution following 
infusion with 13C-labelled glucose (Fig. 2a). As expected, 13C-glucose was quickly oxidised 
via the CAC under normoxia, as indicated by the diagnostic m+2 and m+4 isotopologues of 
the CAC intermediates (Fig. 2b and Extended Data Fig. 3). However, the contribution 
of 13C-glucose to succinate was significantly reduced in ischaemic hearts (Fig. 2b and 
Extended Data Fig. 3). We then assessed the contribution of fatty acid oxidation to the CAC 
activity by perfusing hearts with 13C-palmitate (Fig. 2a and Extended Data Fig. 4a). The 
CAC was readily enriched in 13C-carbons derived from palmitate oxidation (Extended Data 
Fig. 4b). However, the contribution of 13C-palmitate to succinate was strikingly decreased 
during ischaemia (Fig. 2c and Extended Data Fig. 4b). Glutamine was not a major carbon 
source for CAC metabolites in normoxia or ischaemia (Extended Data Fig. 5a) and the 
minimal 13C-glutamine incorporation to α-ketoglutarate was decreased in ischaemia 
(Extended Data Fig. 5b). Finally, inhibition of the GABA shunt with vigabatrin (Fig. 2a)10 
did not decrease ischaemic succinate accumulation (Fig. 2d and Extended Data Fig. 5c,d). 
Together, these data demonstrate that the major carbon sources for the CAC under normoxia 
do not significantly contribute to the buildup of succinate during ischaemia, indicating that 
succinate accumulation is not caused by conventional operation of cardiac metabolism.
To explore other mechanisms that could lead to succinate accumulation during ischaemia, 
we considered earlier speculations that during anaerobic metabolism SDH might act in 
reverse to reduce fumarate to succinate12-14. While SDH reversal has not been demonstrated 
in ischaemic tissues, in silico flux analysis determined succinate production by SDH reversal 
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during ischaemia as the best solution to sustain proton pumping and ATP production when 
metabolites including fumarate, aspartate and malate were available (Fig. 2e, Extended Data 
Fig. 6, and Supplementary Tables 5 and 6). The model predicted that fumarate supply to 
SDH came from two converging pathways: the malate/aspartate shuttle (MAS), where the 
high NADH/NAD ratio during ischaemia drives malate formation that is converted to 
fumarate14-16; and AMP-dependent activation of the purine nucleotide cycle (PNC) that 
drives fumarate production17,18 (Fig. 2e and Extended Data Fig. 6). To test this prediction 
experimentally, we infused mice with dimethyl malonate, a membrane-permeable precursor 
of the SDH competitive inhibitor malonate (Extended Data Fig. 7a-c)19,20. Dimethyl 
malonate infusion strikingly decreased succinate accumulation in the ischaemic myocardium 
(Fig. 2f). This result indicates that SDH operates in reverse in the ischaemic heart, as 
inhibition of SDH operating in its conventional direction would have further increased 
succinate (Fig. 2a, Extended Data Fig. 6 and Supplementary Tables 5 and 6). Therefore 
succinate accumulates during ischaemia from fumarate reduction by the reversal of SDH.
Since aspartate is a common carbon source for fumarate in both the PNC and the MAS 
pathways (Fig. 2e), we used 13C-labelled aspartate to evaluate the contribution of these 
pathways to succinate production during ischaemia. 13C-aspartate infusion significantly 
increased 13C-succinate content of the ischaemic myocardium compared to normoxia (Fig. 
2g). In fact, 13C-aspartate was the only 13C-carbon donor that incorporated substantially into 
succinate during ischaemia (Extended Data Fig. 7d). To characterise the relative 
contributions of the MAS and PNC to ischaemic succinate accumulation we used 
aminooxyacetate (AOA), which inhibits aspartate aminotransferase in the MAS21 (Fig. 2e) 
and 5-amino-1-β-D-ribofuranosyl-imidazole-4-carboxamide (AICAR), which inhibits 
adenylosuccinate lyase in the PNC18,22 (Fig. 2e). Both inhibitors decreased ischaemic 
succinate levels (Fig. 2h). Therefore, our results suggest that during ischaemia both the 
MAS and PNC pathways increase fumarate production, which is then converted to succinate 
by SDH reversal.
To investigate the potential mechanisms underlying succinate-driven mitochondrial ROS 
production we modelled in silico changes in ischaemic cardiac metabolism upon 
reperfusion. The simulations predicted that SDH oxidises the accumulated succinate and, 
with complex III and IV at full capacity, drives reverse electron transport (RET) through 
mitochondrial complex I23-26 (Extended Data Fig. 8a-c). Intriguingly, succinate drives 
extensive superoxide formation from complex I by RET in vitro, making it a compelling 
potential source of mitochondrial ROS during IR26. However, the role of complex I RET in 
IR injury has never been demonstrated. To test whether the succinate accumulated during 
ischaemia could drive complex I RET upon reperfusion, we tracked mitochondrial ROS with 
the fluorescent probe dihydroethidine (DHE), and mitochondrial membrane potential from 
the potential-sensitive fluorescence of tetramethylrhodamine methyl ester (TMRM), in a 
primary cardiomyocyte model of IR injury27. DHE was rapidly oxidised upon reperfusion, 
consistent with increased superoxide production (Fig. 3a)27. Inhibition of SDH-mediated 
ischaemic succinate accumulation with dimethyl malonate reduced DHE oxidation upon 
reperfusion (Fig. 3a). To further assess the role of succinate in driving ROS production, we 
employed a cell permeable derivative of succinate, dimethyl succinate, which is readily 
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taken up by cells, where it is then hydrolysed thereby increasing succinate levels (Extended 
Data Fig. 7b,c). Addition of dimethyl succinate to ischaemic primary cardiomyocytes 
significantly amplified reperfusion DHE oxidation, suggesting that succinate levels 
controlled the extent of reperfusion ROS (Fig. 3b). Importantly, selective inhibition of 
complex I RET with rotenone (Fig. 3c and Extended Data Fig. 9a) or MitoSNO (Fig. 3c) 
abolished both ischaemic succinate and dimethyl succinate-driven DHE oxidation upon 
reperfusion, indicating that ischaemic succinate levels drove superoxide production through 
complex I RET. Succinate-dependent RET was further supported by the observation that 
NAD(P)H oxidation at reperfusion was suppressed by increasing succinate levels with 
dimethyl succinate (Extended Data Fig. 9 b,c). Tracking the mitochondrial membrane 
potential revealed that inhibition of ischaemic succinate accumulation with dimethyl 
malonate slowed the rate of mitochondrial repolarisation upon reperfusion (Fig. 3d and 
Extended Data Fig. 9d-f), consistent with accelerated repolarisation through RET at complex 
I driven by succinate upon reperfusion. Elevating succinate in C2C12 mouse myoblast cells 
with dimethyl succinate while hyperpolarising mitochondria with oligomycin increased 
MitoSOX oxidation independently of IR (Fig. 3e), suggesting that combining high succinate 
levels with a large protonmotive force is sufficient to drive complex I ROS production by 
RET.
We next investigated whether succinate-driven complex I RET leads to ROS production in 
the heart in vivo, during IR injury. To do this we used the ratiometric mass spectrometric 
mitochondria-targeted ROS probe MitoB8. This probe is rapidly taken up by mitochondria 
in the heart in vivo and then oxidised to MitoP by the ROS hydrogen peroxide and 
peroxynitrite. Consequently measuring the MitoP/MitoB ratio by LC-MS/MS indicates 
changes in mitochondrial ROS in vivo8. At the onset of cardiac reperfusion there was an 
increase in the MitoP/MitoB ratio and this increase was prevented by blocking the 
accumulation of ischaemic succinate with dimethyl malonate (Fig 3f). Furthermore, the 
activity of the mitochondrial superoxide-sensitive CAC enzyme aconitase was decreased in 
the first minutes of reperfusion and this oxidative damage was also prevented by infusing 
dimethyl malonate during ischaemia to prevent succinate accumulation (Fig 3g). Together 
these data indicate that succinate oxidation upon reperfusion drives a burst of mitochondrial 
ROS production from complex I by RET during cardiac IR injury in vivo, and that this ROS 
production is prevented by dimethyl malonate.
Our findings suggest the following model (Fig. 4a): during ischaemia fumarate production 
increases, through activation of the MAS and PNC, and is then reduced to succinate by SDH 
reversal. Upon reperfusion, the accumulated succinate is rapidly oxidised to maintain the Q 
pool reduced, thereby sustaining a large protonmotive force by conventional electron 
transport through complexes III and IV to oxygen, while also driving RET at complex I to 
produce the mitochondrial ROS that initiate IR injury26. This model provides a unifying 
framework for many hitherto unconnected aspects of IR injury, such as the requirement for 
time-dependent priming during ischaemia to induce ROS upon reperfusion, protection 
against IR injury by the inhibition of complexes I8 and II28, and by mild uncoupling29.
Intriguingly, our model also generates an unexpected, but testable, prediction. Manipulation 
of the pathways that increase succinate during ischaemia and oxidise it upon reperfusion 
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should determine the extent of IR injury. Since the reversible inhibition of SDH blocks both 
succinate accumulation during ischaemia (Fig. 2f) and its oxidation upon reperfusion, it 
should protect against IR injury in vivo. Intravenous (i.v.) infusion of dimethyl malonate, a 
precursor of the SDH inhibitor malonate, during an in vivo model of cardiac IR injury was 
protective (Fig. 4b,c). Importantly, this cardioprotection was suppressed by adding back 
dimethyl succinate (Fig. 4b,c and Extended data Fig 10a), which restored elevated levels of 
ischaemic succinate (Fig. 4d) indicating that protection by dimethyl malonate resulted solely 
from blunting succinate accumulation. Finally, i.v. infusion of dimethyl malonate during rat 
transient middle cerebral artery occlusion (tMCAO), an in vivo model of brain IR injury 
during stroke, also suppressed ischaemic accumulation of succinate (Fig. 4e and Extended 
Data Fig. 10b) and was protective, reducing the pyknotic nuclear morphology and 
vacuolation of the neuropil (Extended Data Fig. 10c), decreasing the volume of infarcted 
brain tissue caused by IR injury (Fig. 4f,g) and preventing the decline in neurological 
function and sensorimotor function associated with stroke (Fig. 4h and Extended Data Fig. 
10d). These findings support our model of succinate-driven IR injury, demonstrating that 
succinate accumulation underlies IR injury in the heart and brain and suggests decreasing 
succinate accumulation and oxidation as a new therapeutic approach for IR injury.
We have demonstrated that accumulation of succinate, via fumarate production and reversal 
of SDH, is a universal metabolic signature of ischaemia in vivo. In turn, succinate is a 
primary driver of the mitochondrial ROS production upon reperfusion that underlies IR 
injury in a range of tissues. Ischaemic accumulation of succinate may be of further relevance 
via its role in inflammatory and hypoxic signalling10. Thus succinate could contribute to 
both the acute pathogenesis of IR injury by mitochondrial ROS, and then upon secretion also 
trigger inflammation and neovascularisation30. This further suggests that mitochondrial ROS 
produced by RET at complex I may normally act as a redox signal from mitochondria that 
responds to changes in electron supply to the Q pool and ATP demand, but is grossly over-
activated in IR injury. Besides elucidating the metabolic responses that underlie IR injury, 
these data demonstrate that preventing succinate accumulation during ischaemia is 
protective against IR injury in vivo, suggesting novel therapeutic targets for IR injury in 
pathologies such as heart attack and stroke.
METHODS
Animal procedures and ethics statement
All animal experiments described were carried out in accordance with the UK Home Office 
Guide on the Operation of Animal (Scientific Procedures) Act of 1986. The mice used were 
C57BL/6J. The following project licences were used: Krieg (PPL 80/2374), Shattock (PPL 
70/7491), Work (PPL 60/4286) and Saeb-Parsy (PPL 80/2638).
In vivo mouse myocardial experiments
For the in vivo heart IR model an open-chest, in situ heart model was used31,32. Male mice 
(8–10 weeks; Charles River Laboratories, UK) were anaesthetised with sodium 
pentobarbital (70 mg/kg intraperitoneally (i.p.)), intubated endotracheally and ventilated 
with 3 cm H2O positive-end expiratory pressure. Adequacy of anaesthesia was monitored 
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using corneal and withdrawal reflexes. Ventilation frequency was kept at 110 breaths per 
minute with tidal volume between 125 - 150 μL. A thoracotomy was performed and the 
heart exposed by stripping the pericardium. A prominent branch of the left anterior 
descending coronary artery (LAD) was surrounded by a 7-0 Prolene suture that was then 
passed through a small plastic tube. Ischaemia was induced by tightening the tubing against 
the heart surface. To assess metabolites during IR in vivo, mice were divided into four 
groups: 5 min ischaemia, 30 min ischaemia, 30 min ischaemia plus 5 min reperfusion and 30 
min sham-operation in which the suture was placed but the LAD was not occluded. At the 
end of each protocol tissue was removed from the at risk and peripheral areas of the heart, 
selected visually by comparing white versus red tissue, and snap-frozen in liquid nitrogen. 
Sham-operated tissue was removed from the presumed risk zone.
Infarct size was assessed after 30 min of ischaemia followed by 120 min reperfusion using 
2% triphenyltetrazolium chloride staining and is expressed as a percentage of the risk 
zone33. Metabolic inhibitors (all from Sigma) in sterile saline were infused i.v. via a tail vein 
10 min prior to and throughout ischaemia at the following doses: dimethyl malonate (4 
mg/kg/min), AOA (50 μg/kg/min; Fluorochem) and AICAR 10 mg/kg/min). Dimethyl 
succinate (8 mg/kg/min) was infused in combination with dimethyl malonate. Control mice 
were infused with sterile saline. The total volume administered never exceeded 200 μL/
mouse.
Mitochondrial ROS during cardiac IR were assessed by iv injection of 50 nmol of MitoB 
immediately prior to dimethyl malonate or saline infusion as described previously. Hearts 
were snap-frozen in liquid nitrogen following 30 mins ischaemia and 15 mins reperfusion. 
For mice subjected to ischaemia only MitoB was administered at an earlier time-point so 
that probe incubation was time-matched for all groups. ROS was then assessed by 
determination of the MitoP/MitoB ratio by LC-MS/MS relative to deuterated internal 
standards8.
Ex vivo Langendorff heart experiments for metabolomic analysis
Mice were heparinised (200 U i.p.) and anaesthetised with sodium pentobarbital (100 mg/kg 
i.p.). The chest was then opened and the heart rapidly excised and arrested in cold Krebs-
Henseleit (KH) buffer (0.5 mM EDTA, 118 mM NaCl, 4.7 mM KCl, 25 mM NaHCO3, 11 
mM glucose, 1.2 mM MgSO4, 1.2 mM KH2PO4 and 2 mM CaCl2) at pH 7.4. The aorta was 
then cannulated with a 22 G blunt needle and transferred to a perfusion apparatus. The heart 
was perfused with 37°C KH buffer (95% O2/5% CO2) at a constant pressure of 80 mm Hg. 
After 20 min equilibration hearts were separated into four groups: 60 min normoxic 
perfusion; 30 min global ischaemia; 30 min global ischaemia plus 5 min reperfusion; and 30 
min global ischaemia plus 30 mins reperfusion. Metabolic inhibitors were infused for 10 
min prior to ischaemia through a side port above the aortic cannula at 1% of coronary flow. 
At the end of the experiments the hearts were snap-frozen in liquid nitrogen and stored at 
−80°C.
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13C metabolite labelling in ex vivo Langendorff heart experiments
Mice were anaesthetised with sodium pentobarbital (~140 mg/kg). Hearts were rapidly 
excised, cannulated and perfused in the isovolumic Langendorff mode at 80 mm Hg 
perfusion pressure, at 37°C with KH buffer continuously gassed with 95% O2/5% CO2 (pH 
7.4)34. Cardiac function was assessed using a fluid-filled balloon inserted into the left 
ventricle (LV), and connected to a pressure transducer and a PowerLab system 
(ADInstruments, UK). Balloon volume was adjusted to an initial LV diastolic pressure of 4 - 
9 mm Hg34 and all hearts were paced at 550 bpm. Left ventricular developed pressure 
(LVDP) was calculated from the difference between systolic (SP) and diastolic pressures 
(DP). Functional parameters (SP, end diastolic pressure, heart rate, LVDP, coronary flow, 
perfusion pressure) were recorded continuously using LabChart software v.7 
(ADInstruments, UK).
After 20 min equilibration with standard KH buffer, hearts were divided into the following 
groups: perfused with KH buffer containing 11 mM U-13C Glucose followed by 30 min 
normoxic respiration (n=4/group); perfused for 10 min with glucose-free KH buffer 
containing 11 mM U-13C glucose and then subjected to 30 min global normothermic 
ischaemia (n=4/group); perfused with KH buffer containing 0.3 mM U-13C potassium 
palmitate for 10 min followed by: continued perfusion for 30 min normoxic respiration 
(n=4/group), or 30 min global normothermic ischaemia (n=4/group); perfusion of KH buffer 
containing 1 mM 5-13C L-glutamine for 10 min followed by standard normoxic perfusion 
for 30 min with unlabeled KH buffer (n=4);10 min perfusion with 1 mM 13C5 L-glutamine, 
followed by 30 min global ischaemia (n=4); 10 min perfusion of 1mM 1-13C L-aspartic 
acid, followed by normoxic perfusion for 30 min with unlabeled KH buffer; 10 min 
perfusion with 1mM 1-13C L-aspartic acid, followed by 30 min global ischaemia. At the end 
hearts were snap frozen in liquid nitrogen and stored at −80°C.
In vivo rat brain ischaemia and reperfusion
Male spontaneously hypertensive stroke prone (SHRSP) rats from the colony maintained at 
the University of Glasgow (270–310 g) were anaesthetised with 5% isoflurane in oxygen 
and were intubated and ventilated throughout surgery (~2.5% isoflurane/oxygen). Body 
temperature was maintained at 37 ± 0.5°C. Animals underwent pre-stroke burrhole 
surgery35 before transient middle cerebral artery occlusion (tMCAO, 45 min). Briefly, a 
silicone-coated monofilament (Doccol Corporation, USA) was advanced through the 
common carotid artery to block the origin of the MCA36. Animals were maintained under 
anaesthesia during ischaemia. Immediately following removal of the filament, or after 5 
mins of reperfusion, the brain was removed following cervical dislocation and infarct tissue 
separated from surrounding tissue on the ipsilateral side and snap-frozen in liquid nitrogen 
for metabolomic analysis. Corresponding regions were taken from the contralateral side. A 
separate group was infused with dimethyl malonate (6 mg/kg/min) by i.v. infusion 10 min 
prior to and during tMCAO) or carrier, allowed to recover for 3 days, over which time they 
were scored for neurological function37 as modified38, and locomotor and sensorimotor 
activity by the tapered beam walk test, quantifying the average number of footfalls as 
described previously38. These rats were then sacrificed by transcardiac perfusion fixation 
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and the infarct area was assessed across 7 coronal levels following hematoxylin and eosin 
staining39.
In vivo mouse renal ischaemia and reperfusion
Under isofluorane general anaesthesia, mice underwent laparotomy and exposure of the 
renal hilum bilaterally. Vascular clips (8 mm, InterFocus Fine Science Tools, Cambridge, 
UK) were placed over one renal hila to induce unilateral renal ischaemia. At the end of 45 
min ischaemia the clip was removed and reperfusion of the kidney noted as return of blush 
colour and visualisation of flow from the renal vein. Kidneys were taken at the end of 
ischaemia, or following 5 min reperfusion and snap-frozen in liquid nitrogen for 
metabolomic analysis.
In vivo mouse liver warm ischaemia
Mice were killed by cervical dislocation to ensure cessation of blood flow. Liver tissue was 
maintained in situ in the body cavity for 45 min at 37°C through use of a thermostated heat 
pad followed by removal and snap-freezing on liquid nitrogen for subsequent metabolomic 
analysis.
Metabolomic analyses
Equal amounts wet weight murine tissue were lysed in 250 μL extraction solution (ES; 30% 
acetonitrile, 50% methanol and 20% water) per 10 mg tissue in Precellysis 24 vials, 
following the manufacturer’s instructions. The suspension was immediately centrifuged 
(16,000 g, 15 min at 0°C) and the supernatant used for LC-MS analysis. For the LC 
separation, column A was Sequant Zic-Hilic (150 mm × 4.6 mm, internal diameter 3.5 μm) 
with a guard column (20 mm × 2.1 mm 3.5 μm) from HiChrom, Reading, UK. Mobile 
phases. A: 0.1% formic acid (v/v) in water. B: 0.1% formic acid (v/v) in acetonitrile. Flow 
rate 300 μL/min. Gradient: 0-3 min 80 % B, 25 min 20% B, 26 min 80 % B, 36 min 80% B. 
Column B was sequant Zic-pHilic (150 mm × 2.1 mm i.d. 3.5 μm) with guard column (20 
mm × 2.1 mm i.d. 3.5 μm) from HiChrom, Reading, UK. Mobile phases. C: 20 mM 
ammonium carbonate plus 0.1% ammonium hydroxide in water. D: acetonitrile. Flow rate 
100 μL/min. Gradient: 0 min 80% D, 28 min 20% D, 29 min 80% D, 45 min 80% D. The 
mass spectrometer (Thermo QExactive Orbitrap) was operated in full MS and polarity 
switching mode. Samples were randomised in order to avoid machine drifts. Spectra were 
analysed using both targeted and untargeted approaches. For the targeted approach spectra 
were analysed using XCalibur Qual Browser and XCalibur Quan Browser softwares 
(Thermo Scientific) by referencing to an internal library of compounds. For the untargeted 
approach spectra were processed with Sieve 2.0 software (Thermo Scientific) and spectral 
peaks were extracted. The arrays of spectra were then statistically analysed using the 
functions explore.data and univariate of the R package muma40. Statistical analysis of 
datasets followed established parameters for determination of significance and data 
distribution for metabolomics datasets40,41. Briefly, Shapiro Wilk’s test for normality was 
performed for every metabolite in each experimental condition. When the p-value from 
Shapiro Wilk’s test was greater than 0.05, Welch’s t Test was performed, otherwise 
Wilcoxon-Mann Whitney Test was performed. P-values were corrected for multiple testing 
Chouchani et al. Page 9
Nature. Author manuscript; available in PMC 2015 May 20.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
using Benjamini-Hochberg correction. Metabolite abundance differences were considered 
significant when final corrected p-value was lower than 0.05.
In situ ischaemia and reperfusion of adult rat primary cardiomyocytes
Male Sprague-Dawley rats (300-370 g) were terminally anaesthetised via IP injections of 
200 mg/kg sodium pentobarbitone and 330 U/kg heparin. Hearts were excised and 
retrograde perfused on a Langendorff-perfusion system with 13 mL/min oxygenated KH 
buffer at 37°C. Cells were isolated by collagenase digestion using standard methods42. 
Briefly, hearts were perfused for 5 min with KH buffer, then 5 min with Ca2+-free KH 
buffer containing 100 μM EGTA, followed by 8 min with KH buffer containing 100 μM 
CaCl2 and 0.5 mg/ml collagenase II (Worthington). The heart was removed from the 
cannula and ventricles quickly chopped and bathed in 20 mL of the same collagenase buffer 
for 15 min. Digested tissue was passed through a 100 μm cell filter, and cells were collected 
by gravity. The supernatant was removed and cells were washed with KH buffers containing 
first 0.5 mM CaCl2, then 1 mM CaCl2. Typical yields were 2 × 106 cells/heart with 90% 
viable, rod-shaped cells. The cells were resuspended in Medium 199 (supplemented with 5 
mM creatine, 2 mM carnitine, 5 mM taurine, and 100 μg/mL penicillin/streptomycin) and 
plated onto coverslips coated with laminin (Sigma). After 1 h incubation at 37°C/5% CO2, 
unattached cells were washed off, and fresh Medium 199 was added to each well for at least 
4 h at 37°C/5% CO2.
Cells were imaged within 36 h of plating. Images using a Zeiss LSM 510 META confocal 
microscope with a Fluar 20×/0.75NA UV objective, or a microscope equipped with an Orca 
ER cooled CCD camera (Hamamatsu), a monochrometer (Cairn Research) and emission 
filter wheel (Prior) with a Fluar 20×/0.75NA objective. Cells attached to coverslips, which 
formed the base of custom built imaging chambers, were placed on a heated stage at 37°C 
on the microscope with normoxic recording buffer (156 mM NaCl, 3 mM KCl, 2 mM 
MgSO4, 1.25 mM K2HPO4, 2 mM CaCl2, 10 mM Hepes, 10 mM D-Glucose; pH 7.4). 
Simulated ischaemia was achieved by replacing the buffer with a pre-gassed, hypoxic 
recording buffer simulating ischaemia (as above but lacking glucose and containing 10 mM 
sodium lactate, 14.8 mM KCl; pH 6.4) and by covering the heated stage with a transparent, 
gas-impermeant lid, forming a small chamber into which argon was forced to maintain 
hypoxia. pO2 was routinely measured as < 2.0 mm Hg during simulated ischaemia. To 
simulate reperfusion, the lid was removed from the chamber, and the buffer replaced with 
normoxic recording buffer.
Mitochondrial membrane potential was measured using tetramethylrhodamine, methyl ester 
(TMRM, Life Technologies) in dequench mode. In this mode, mitochondrial depolarisation 
causes redistribution of a high concentration of quenched TMRM from mitochondria to 
cytosol, where the lower concentration results in dequenching and an increase in 
fluorescence27. Cells were loaded at room temperature with normoxic recording buffer 
containing 3 μM TMRM for 30 min. Prior to imaging, loading buffer was removed and 
replaced with normoxic recording buffer. TMRM fluorescence was excited at 543 nm and 
emission was collected using a LP 560 filter.
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ROS production was estimated by oxidation of DHE and ratiometric assessment. For this 
cells were loaded with 5 μM dihydroethidium (DHE, Invitrogen), which remained present 
throughout normoxic and ischaemic conditions. DHE was excited at 351 nm and the emitted 
signal was acquired with a BP 435-485 IR filter. Oxidised DHE was excited at 543 nm and 
emission was collected with a LP 560 filter. NADH autofluorescence was excited at 351 nm 
and the emitted signal was collected using a BP 435-485IR filter. All measured cell 
parameters were analysed with Fiji image processing software.
Assessment of succinate-dependent mitochondrial superoxide production in myoblasts
C2C12 myoblasts were seeded in 35 mm glass bottom culture dishes (MatTek) and 
incubated for 24 h in low glucose (1 g/L) DMEM. 2 h prior to imaging DMEM was 
removed, and replaced with imaging buffer (132 mM NaCl; 10 mM HEPES; 4.2 mM KCl; 1 
mM MgCl2 1 mM CaCl2 adjusted to pH 7.4 with Tris base and supplemented with 2-
deoxyglucose (25 μM), and sodium pyruvate (10 mg/L or 4 μM oligomycin as indicated). 
Myoblasts were pre-incubated with 2 μM MitoSOX for 15 min prior to imaging. MitoSOX 
fluorescence was monitored using a Nikon Eclipse Ti confocal microscope at 37°C on a 
temperature controlled stage for 30 min. MitoSOX was excited at 510 nm and the emitted 
signal collected with a LP 560 filter following the indicated additions.
In silico analysis of metabolic flux during ischaemia and reperfusion
Simulations were performed using an expanded version of the myocardial mitochondrial 
metabolic model iAS25311. The model was expanded to include additional mitochondrial 
reactions by using the latest version of MitoMiner, a mitochondrial proteomics database43. 
MitoMiner was used to identify new mitochondrial reactions for inclusion by cross-
referencing these data with information from BRENDA44, HumanCyc45 and relevant 
literature to confirm that the new reactions are present in human, expressed in heart tissue 
and localised to the mitochondrial matrix. In addition, cytosolic reactions were included that 
could contribute to energy production, such as amino acid degradation and conversion 
reactions as well as the purine nucleotide cycle. Protonation states of metabolites in the 
model were calculated by using the Marvin suite of computational chemistry software 
(ChemAxon Ltd, Budapest, Hungary). Reactions were then charge-balanced according to 
the protonation state of the major microspecies found at pH 8.05 for the mitochondrial 
matrix46 and pH 7.30 for the cytosol. In addition directionality constraints were imposed 
based upon general rules of irreversibility, thermodynamics and information from public 
resources such as BRENDA and HumanCyc and capacity constraints were taken from the 
literature11. The final model contained 227 mitochondrial matrix reactions, 76 cytosolic 
reactions, 91 transport steps between the two compartments and 84 boundary conditions 
representing inputs and outputs into the system. The expanded model is a manually curated 
and highly refined model of the mitochondrion, and as with iAS253, no metabolite dead 
ends were present and all reactions were capable of having flux.
Metabolism of the mitochondrial network was simulated using flux balance analysis, a 
technique that has been described in detail47. The objective function used to optimise the 
reaction fluxes was maximum ATP production. All the FBA simulations were carried out 
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using MATLAB R2012b (Math Works, Inc, Natick, MA) with the COBRA Toolbox48, and 
the linear programming solver GLPK (http://www.gnu.org/software/glpk).
To represent ischaemia, the maximum uptake of oxygen was reduced to 20% of its level 
under normal conditions (4.0 vs. 19.8 μmol/min/gram dry weight). Simulations were run 
with boundary conditions for metabolites set to either their normoxic values, or with various 
metabolites in excess to determine if they could contribute to ATP production under 
ischaemia. To represent reperfusion, the oxygen level was restored to its normal level and 
simulations were run with the availability of succinate, lactate, pyruvate and NADH 
increased to various levels to reflect the ischemic accumulation of these metabolites. The 
flux capacity of ATP synthase was reduced by up to 50% to represent the delay in 
generating ADP from AMP required for ATP synthase to function and also to model hyper-
polarisation of the mitochondrial membrane, in effect by constraining the efficiency of the 
other proton pumping complexes of the electron transport chain.
Assessment of mitochondrial aconitase inactivation in mouse heart tissue
Aconitase activity was measured as described previously49. Briefly, following the relevant 
in vivo intervention (normal respiration, or 30 min ischaemia and 15 min reperfusion ± 
dimethyl malonate), mouse hearts were rapidly excised and homogenised in mitochondrial 
isolation buffer (250 mM sucrose, 2 mM EDTA, 10 mM sodium citrate, 0.6 mM MnCl2, 
100 mM Tric-HCl, pH 7.4) followed by mitochondrial isolation by differential 
centrifugation. Samples (10 μL; 1-2μg mitochondrial protein) were added to a 96 well plate 
and 190 μl assay buffer (50 mM Tris-Cl (pH 7.4), 0.6 mM MnCl2, 5 mM sodium citrate, 0.2 
mM NADP+, 0.1% (v/v) Triton X-100, 0.4UmL−1 ICDH). Absorbance was measured at 340 
nm for 7 min at 37 °C. To determine the background rate of NADPH reduction, 100 μM 
fluorocitrate was added in a parallel experiment. In all cases the background NADPH 
reduction was <10% of the observed rate. In parallel, we determined the citrate synthase 
activity of each sample50. To control for mitochondrial content we normalised aconitase 
activity to the citrate synthase activity and expressed the result as a percentage of control 
levels.
Statistics and experimental design
Data were expressed as mean ± s.e.m and P values were calculated using two-tailed 
Student’s t-test for pairwise comparisons, and one way ANOVA followed by Bonferroni’s 
test for multiple comparisons, unless otherwise stated. Experimenters analysing samples 
from metabolomics, histological, and neurological animal experiments were blinded to the 
experimental interventions.
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Extended Data
Extended Data Figure 1. 
Comparative analysis of metabolites significantly accumulated in ischaemic conditions. a, 
Various murine tissues exposed to sufficient periods of ischaemia to prime for reperfusion 
ROS production were subjected to targeted LC-MS metabolomics analysis and comparison 
of metabolites that accumulated significantly when compared to normoxic levels. Following 
this, metabolites were scored according to the prevalence of their accumulation across five 
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ischaemic tissue conditions. B = brain, H = whole heart ischaemia ex vivo, HL = LAD 
ischaemia in vivo, K = kidney, L = liver. b, Determination of linearity of the relationship 
between LC-MS metabolite peak intensity and concentration for CAC and related 
metabolites. c, Quality control determination of coefficient of variation for LC-MS 
quantification of CAC and related metabolites.
Extended Data Figure 2. 
Timecourse of succinate levels in the in vivo heart during ischaemia and reperfusion and 
potential metabolic inputs for succinate. a, Time course of succinate levels during 
myocardial ischaemia and reperfusion for the in vivo heart (5 min and 15 min ischaemia n = 
4; 30 min ischaemia n = 9; 5 min reperfused n = 5). b, Summary of the three potential 
metabolic inputs for succinate-directed ischaemic flux. To understand the metabolic 
pathways that could contribute to succinate production under ischaemia, an updated version 
of the iAS253 model of cardiac metabolism was employed to simulate ischaemia using flux 
balance analysis. The model showed three possible mechanisms for producing succinate: 
from α-ketoglutarate produced by the CAC, derived from glycolysis, fatty acid oxidation, 
and glutaminolysis (grey box), from succinic semialdehyde produced from the GABA shunt 
(blue box), and from fumarate produced from the malate-aspartate shuttle and purine 
nucleotide cycle (red box) via the reversal of SDH. Data are shown as the mean ± s.e.m of at 
least four biological replicates.
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Extended Data Figure 3. 
Metabolic labelling of CAC and proximal metabolites by 13C glucose in the ischaemic and 
normoxic myocardium. Proportional isotopic labelling profile of CAC and proximal 
metabolites during normoxic and ischaemic myocardial perfusion. Mouse hearts were 
perfused with 11 mM 13C glucose for 10 min followed by either 30 min no flow ischaemia 
or 30 min normoxic perfusion followed by snap-freezing and LC-MS metabolomic analysis 
(n = 4). * p < 0.05, ** p < 0.01, *** p < 0.001. Data are shown as the mean ± s.e.m of at 
least four biological replicates.
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Extended Data Figure 4. 
Metabolic labelling of CAC and proximal metabolites by 13C palmitate in the ischaemic and 
normoxic myocardium a, Mouse hearts were perfused with 0.3 mM 13C palmitate (+16 
labelled) for 10 min resulting in a significant proportion of the endogenous palmitate pool 
being +16 labelled. Following this, hearts were subjected to either 30 min ischaemia or 
continued normoxic respiration with 13C palmitate followed by snap-freezing and 
metabolomic analysis. b, Isotopic flux from palmitate to CAC and proximal metabolites 
following normoxic and ischaemic myocardial respiration. The isotopic profile for each 
metabolite is expressed as a proportion of the total pool (n = 4). * p < 0.05, ** p < 0.01, *** 
p < 0.001. Data are shown as the mean ± s.e.m of at least four biological replicates.
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Extended Data Figure 5. 
Metabolic labelling of CAC and proximal metabolites by 13C glutamine in the ischaemic 
and normoxic myocardium, and measurement of the effect of inhibition of GABA 
transaminase succinate accumulation in the ischaemic myocardium. a, Mouse hearts were 
perfused with 4 mM 13C glutamine (+5 labelled) for 10 min followed by either 30 min no 
flow ischaemia or 30 min normoxic respiration followed by snap freezing and metabolomic 
analysis. The isotopic profile for each metabolite is expressed as a proportion of the total 
pool (n=4) b, Additionally, flux to α-KG was determined relative to the proportion of the +5 
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glutamine pool in the heart (n = 4). c, Perfused mouse hearts were subjected to 30 min no 
flow ischaemia ± continuous infusion of vigabatrin (Vig; 100, 300, and 700 μM) 10 min 
prior to ischaemia. Heart tissue was snap frozen and c, GABA and d, succinate abundance 
quantified relative to normoxic levels by LC-MS (n = 4; ischaemia n = 5). * p < 0.05. Data 
are shown as the mean ± s.e.m of at least four biological replicates.
Extended Data Figure 6. 
Unabridged metabolic model identifying pathways that can become activated by tissue 
ischaemia to drive succinate accumulation. To identify the metabolic pathways that could 
contribute to succinate production under ischaemia, we simulated these conditions using 
flux balance analysis in conjunction with an expanded version of the iAS253 mitochondrial 
model of central cardiac metabolism. The major pathways contributing to succinate 
accumulation (bold red lines) were via fumarate feeding into the reverse activity of SDH. 
This was produced by the purine nucleotide cycle (PNC) and the malate-aspartate shuttle 
(MAS), which consumed glucose and aspartate, and also led to significant production of 
lactate and alanine. Lesser sources of succinate (thin red lines) included glycolysis and 
glutaminolysis but this was relatively minor as this route was constrained by the 
overproduction of NADH. In addition a small amount of fumarate was generated by 
pyruvate carboxylase activity. The GABA shunt did not contribute (black dashed line).
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Extended Data Figure 7. 
Effects of dimethyl malonate and dimethyl succinate treatment of cells and in vivo on 
intracellular accumulation of malonate and succinate, and respiration and comparison of 13C 
ischaemic metabolite fluxes to succinate relative to isotopic donor pools. a, Intravenous 
infusion of dimethyl malonate in vivo results in accumulation of malonate in the ischaemic 
myocardium (n = 4). b,c, C2C12 cells were incubated with: no additions, glucose, 5 mM 
dimethyl succinate, 5 mM dimethyl malonate, or 5 mM dimethyl malonate and 5 mM 
dimethyl succinate. Cellular oxygen consumption rate due to (b) ATP synthesis and (c) 
maximal rates in the presence of FCCP were determined using a Seahorse XF96 analyser (n 
= 4). d, Mouse hearts were perfused with 13C-glucose (+6 labelled), 13C-glutamine (+5 
labelled), 13C-aspartate (+1 labelled), or 13C-palmitate (+16 labelled) for 10 min followed 
by 30 min no flow ischaemia or 30 min normoxic respiration, followed by snap-freezing and 
metabolomic analysis. To compare the relative magnitude of metabolite flux from each 
carbon source, 13C incorporation to succinate during normoxia and ischaemia was 
determined relative to the proportion of the labelled pool of the relevant infused 13C 
donor. 13C incorporation into succinate was considered in terms of the proportion of the +4 
isotope in the entire succinate pool for 13C-glucose, 13C-glutamine and 13C-palmitate 
infusions; and the proportion of the +1 isotope in the entire pool for the 13C-aspartate 
infusion. (n = 4), *, p < 0.05; ***, p < 0.001. Data are shown as the mean ± s.e.m of at least 
four biological replicates.
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Extended Data Figure 8. 
Predicted changes in pathways of succinate and OXPHOS metabolism during ischaemia and 
following reperfusion. To determine possible changes in succinate metabolism during 
ischaemia, reperfusion and normoxia, cardiac metabolism was simulated in these conditions 
using an expanded version of the iAS253 model with flux balance analysis. The simulations 
predicted that: a, under ischaemia, complex II ran in reverse by using ubiquinol produced by 
complex I to reduce fumarate to succinate, thereby acting as a terminal electron acceptor 
instead of oxygen. Fumarate was produced from the purine nucleotide cycle (PNC) and 
reversal of the citric acid cycle (CAC). Flux through the rest of the respiratory chain was 
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diminished and AMP was produced from ADP due to insufficient ATP production. b, With 
oxygen restored complex II metabolised excess succinate. A delay in regenerating AMP to 
ADP, as typified in the first minute of reperfusion, limited the flux through ATP-synthase. 
This in turn prevented complex III consuming all the ubiquinol generated by complex II, as 
the membrane became hyper-polarised. The excess flux of ubiquinol and protons forced 
complex I to run in reverse, which would generate ROS by RET. c, Once the flux of 
succinate was reduced to normal levels, as in the transition from late reperfusion to 
normoxia, the fluxes through the respiratory chain and citric acid cycle returned to normal.
Extended Data Figure 9. 
Tracking DHE oxidation, NAD(P)H reduction state, and mitochondrial membrane potential 
in primary cardiomyocytes during in situ IR. a, Inhibition of mitochondrial complex I RET 
reduces DHE oxidation on reperfusion (n = 6; rotenone n =4). b,c Effect of manipulation of 
ischaemic succinate levels on NAD(P)H oxidation during early reperfusion (n = 3). Primary 
rat cardiomyocytes were subjected to 40 min ischaemia followed by reoxygenation and 
NAD(P)H reduction state was tracked throughout the experiment by measurement of 
NAD(P)H autofluorescence. Ischaemic buffer contained either no additions, 4 mM dimethyl 
malonate, or 4 mM dimethyl succinate. Average (b) and representative (c) traces from each 
condition are shown. The highlighted window in (c) indicates the period of the experiment 
expanded in detail in (b). d, Effect of inhibition of ischaemic succinate accumulation on 
mitochondrial membrane potential following late ischaemia (left panels) and early 
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reperfusion (right panels). e,f, Primary rat cardiomyocytes were subjected to 40 min 
ischaemia and reoxygenation and mitochondrial membrane potential was tracked throughout 
the experiment by measurement of tetramethylrhoadmine (TMRM) fluorescence. Ischaemic 
buffer contained either no additions or 4 mM dimethyl malonate. (e), TMRM signal 
throughout the entire experiment. (f) TMRM signal during the transition from ischaemia to 
reoxygenation (n = 3). Data are shown as the mean ± s.e.m of at least three biological 
replicates. Replicates represent separate experiments on independent cell preparations.
Extended Data Figure 10. 
Quantification of CAC intermediates in the heart following infusion of dimethyl succinate 
and in the brain following infusion of dimethyl malonate, and extended summary 
cytoprotection and neurological scores of rats subjected to tMCAO IR in vivo ± dimethyl 
malonate infusion. a, Effect of intravenous infusion of dimethyl succinate on CAC 
metabolite abundance in the ischaemic and non-ischaemic myocardium(normoxia and 
peripheral heart tissue + dimethyl succinate n = 3; ischaemia + dimethyl succinate n = 4; α-
KG and aconitate in peripheral heart tissue n = 2). b, Profile of mitochondrial CAC 
metabolite levels following tMCAO ischaemia ± dimethyl malonate (n = 4). c, 
Representative images of cross-sections from rat brains after undergoing tMCAO in vivo ± 
treatment with dimethyl malonate. Brains were treated with hematoxylin and eosin to 
delineate infarcted tissue. d, Locomotor and sensorimotor assessment of rats by 
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quantification of average number of footfalls following tCMAO ± dimethyl malonate 
(control n = 6; dimethyl malonate n = 4). *, p < 0.05; **, p < 0.01. Data are shown as the 
mean ± s.e.m of at least three biological replicates, unless otherwise stated.
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Figure 1. 
Comparative metabolomics identifies succinate as a potential mitochondrial metabolite that 
drives reperfusion ROS production. a, Comparative metabolomics strategy. b, HIVE plot 
comparative analysis. All identified metabolites are identified on the horizontal axis, while 
those accumulated (top axis) or depleted (bottom axis) in a particular ischaemic tissue are 
indicated by a connecting arc. Metabolites accumulated commonly across all tissues are 
highlighted. c, Prevalence of accumulation of metabolites in murine tissues during 
ischaemia. d, Profile of mitochondrial CAC metabolite levels following ischaemia across 
five ischaemic tissue conditions. (in vivo heart n = 5; succinate and fumarate n = 9), (ex vivo 
heart n = 4), (liver n = 4), (brain n = 3), (kidney n = 4). e, Time course of CAC metabolite 
levels during myocardial ischaemia and reperfusion for 5 min in the ex vivo heart (n = 4). f, 
CAC metabolite levels during in vivo myocardial IR in at risk and peripheral heart tissue 
following ischaemia and after 5 min reperfusion. (n = 5; succinate and fumarate n = 9). g, 
CAC metabolite levels during in vivo brain IR following ischaemia and following 5 min 
reperfusion (n = 3). h, CAC metabolite levels during in vivo kidney IR following ischaemia 
and after 5 min reperfusion (n = 4; aconitate n = 3). ** p < 0.01, *** p < 0.001. Data are 
shown as the mean ± s.e.m of at least three biological replicates.
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Figure 2. 
Reverse SDH activity drives ischaemic succinate accumulation by the reduction of fumarate. 
a, Potential inputs to succinate-directed flux by conventional cardiac metabolism and 13C-
metabolite labelling strategy. b, c, 13C isotopologue profile of succinate in the normoxic and 
ischaemic myocardium following infusion of (b) 13C-glucose and (c) 13C-palmitate (n = 4). 
d, Effect of inhibition of GABA shunt with vigabatrin on GABA and succinate levels in the 
ischaemic myocardium (n = 4; ischaemia n = 5). e, Summary of in silico metabolic 
modelling of potential drivers of ischaemic succinate accumulation, and 13C-aspartate 
metabolic labelling strategy. f, Effect of SDH inhibition by dimethyl malonate on CAC 
metabolite abundance in the ischaemic myocardium in vivo (n = 3). g, Relative incorporation 
of 13C-aspartate to the indicated CAC metabolites in the normoxic and ischaemic 
myocardium (n = 4). h, Effect on CAC metabolite abundance in the ischaemic myocardium 
in vivo of blocking aspartate entry into the CAC through AOA-mediated inhibition of 
aspartate aminotransferase, or blocking PNC by inhibition of adenylosuccinate lyase with 
AICAR (n = 3). * p < 0.05, ** p < 0.01, *** p < 0.001. Data are shown as the mean ± s.e.m 
of at least three biological replicates.
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Figure 3. 
Ischaemic succinate levels control ROS production in adult primary cardiomyocytes and in 
the heart in vivo. a, b, DHE oxidation during late ischaemia and early reperfusion ± (a) 
inhibition of ischaemic succinate accumulation (no additions n = 6; dimethyl malonate n = 
5) or (b) addition of dimethyl succinate during ischaemia (n = 6). c, Inhibition of 
mitochondrial complex I RET reduces DHE oxidation on reperfusion following addition of 
dimethyl succinate. Ischaemia (Isch). (n = 5; dimethyl succinate n = 6). d, Effect of dimethyl 
malonate on mitochondrial repolarisation at reperfusion as determined by the rate of TMRM 
quenching (n = 3). e, Effect of dimethyl succinate and oligomycin on mitochondrial ROS in 
aerobic C2C12 myoblasts (n = 4). f, g. Effect of inhibition of ischaemic succinate 
accumulation by dimethyl malonate on mitochondrial ROS during IR injury in vivo assessed 
by (f) MitoB oxidation (n = 5; dimethyl malonate n = 6), and by (g) aconitase inactivation (n 
= 4). * p < 0.05, ** p < 0.01. Data are shown as the mean ± s.e.m of at least three biological 
replicates. For cell data replicates represent separate experiments on independent cell 
preparations.
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Figure 4. 
NADH and AMP sensing pathways drive ischaemic succinate accumulation to control 
reperfusion pathologies in vivo through mitochondrial ROS production. a, Model of 
succinate accumulation during ischaemia and superoxide formation by RET during 
reperfusion. b, Representative cross-sections from mouse hearts following myocardial 
infarction ± inhibition of ischaemic succinate accumulation and reintroduction of ischaemic 
succinate. Infarcted tissue is white, the rest of the area at risk is red, and non-risk tissue is 
dark blue. c, Quantification of myocardial infarct size as described in (b). (n = 6). d, Effect 
of i.v infusion of dimethyl succinate in combination with SDH inhibition by dimethyl 
malonate on CAC metabolite abundance in the ischaemic myocardium in vivo (n = 4). e, 
Effect of i.v infusion of dimethyl malonate on succinate accumulation in the ischaemic brain 
in vivo (n = 4). f-h, Protection by dimethyl malonate against brain IR injury in vivo. 
Quantification of brain infarct volume (f) and rostro-caudal infarct distribution (g) ± 
dimethyl malonate following brain IR injury by tMCAO in vivo (untreated n = 6; dimethyl 
malonate n = 4). (h) Neurological scores for rats following tMCAO ± dimethyl malonate 
(untreated n = 6; dimethyl malonate n = 4). * p < 0.05, ** p < 0.01, *** p < 0.001. Data are 
shown as the mean ± s.e.m of at least three biological replicates, except for h, for which data 
are median ± C.I.
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